The recent advancements by Acurx Pharmaceuticals, Inc. in the development of ibezapolstat, including the scheduling of an End of Phase 2 (EOP2) meeting with the FDA for late April 2024 and the acquisition of SME designation from the European Medicines Agency (EMA), are bullish indicators for the company and its stakeholders. These milestones are significant as they not only validate the potential of ibezapolstat as a novel treatment for C. difficile Infection (CDI) but also underscore the regulatory progress towards a New Drug Application (NDA) filing. The FDA's agreement to hold an EOP2 meeting suggests a positive view on the data and development plan presented by Acurx, potentially smoothing the path towards Phase 3 trials and eventual market approval. Meanwhile, the SME designation by the EMA provides financial and regulatory support, enhancing Acurx's ability to navigate the complex process of obtaining EU Marketing Authorization. These developments demonstrate Acurx's capability to advance through the regulatory landscape efficiently, promising reduced time to market and a competitive edge in the antibiotics sector, making it an attractive prospect for investors and partners.
We are at support for the trading range, 786 retrace confluence with Bottom side LVN, I doubt the market wants to send this stock lower, no aggressive selling as yet at this range. unless there is a need for liquidity for the big boys before sending us higher.
Good Luck!
トレード稼働中:
$2.15 will average down.